The Short List: Current Top 10 Most Shorted Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Should l Buy NTLA?
Source: Benzinga
Reasons for Short Selling: Traders short stocks to either bet on a decline in value or to profit from potential short squeezes, where rising prices force short sellers to buy back shares, creating a feedback loop of increasing demand.
Characteristics of Heavily Shorted Stocks: Stocks become heavily shorted when experienced traders believe they are overvalued, indicating serious risks, while retail traders may see high short interest as an opportunity for quick gains.
Top Heavily Shorted Stocks: As of November 26, 2025, the most shorted stocks include The Wendy's Co. (WEN) at 55.36% short interest, followed by Cambium Networks Corp. (CMBM) and Lucid Group, Inc. (LCID).
Risks and Volatility: While short squeezes can lead to significant gains, they come with high risks and volatility, necessitating careful monitoring and due diligence by traders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 13.780
Low
4.00
Averages
16.50
High
54.00
Current: 13.780
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INTELLIA THERAPEUTICS STOCK RISES 2% FOLLOWING US FDA'S LIFTING OF CLINICAL HOLD ON HEART DISEASE GENE THERAPY TRIAL
- Stock Performance: Intelia Therapeutics shares increased by 2% following a positive development in their clinical trial results.
- Clinical Trial Focus: The trial is centered on gene therapy for treating heart disease, specifically targeting a gene associated with the condition.
See More
Intellia Therapeutics FDA Lifts Clinical Hold on Nexizuran Trials
- Clinical Trial Progress: Intellia Therapeutics announced that the FDA has lifted the clinical hold on its phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), resulting in a 12% stock price increase on Monday, reflecting renewed market confidence in the drug.
- Historical Context: The clinical holds were imposed in October due to observed Grade 4 liver transaminase elevations and increased total bilirubin in a patient treated with nex-z, but both the MAGNITUDE and MAGNITUDE-2 trials have had their holds lifted, indicating progress in addressing safety concerns.
- Partnership Dynamics: The development of nex-z is in collaboration with Regeneron Pharmaceuticals, highlighting a joint effort to provide new treatment options for patients suffering from hereditary transthyretin amyloidosis with polyneuropathy, which could enhance patient outcomes.
- Financial Performance: Intellia reported a GAAP EPS of -$0.83 for Q4 2025, beating expectations by $0.12, while revenue reached $23.02M, exceeding forecasts by $10.85M, showcasing the company's potential in research and market expansion.
See More
Intellia Therapeutics Receives FDA Approval for Clinical Trial
- FDA Lifts Clinical Hold: The FDA has lifted the clinical hold on Intellia's MAGNITUDE trial, allowing the company to continue evaluating the efficacy and safety of nex-z in patients with transthyretin amyloidosis, which accelerates the advancement of its treatment options.
- Trial Enrollment Plans: Intellia aims to complete enrollment of approximately 1,200 patients in the MAGNITUDE trial and 60 patients in the MAGNITUDE-2 trial, ensuring data integrity and smooth trial progression, thereby laying the groundwork for future drug approval.
- Positive Stock Reaction: Intellia's shares rose 8.85% on Monday, reflecting a strong market reaction to the FDA's decision, with a 20% increase over the past 12 months indicating a favorable long-term trend for the company.
- Optimistic Analyst Ratings: The stock carries a Buy rating with an average price target of $19.73, with Chardan Capital and HC Wainwright & Co. maintaining and raising their targets, indicating strong market confidence in Intellia's future developments.
See More
Intellia's Shares Jump as FDA Lifts Hold on Nexiguran Trial
- FDA Lifts Clinical Hold: The FDA's decision to lift the clinical hold on Intellia Therapeutics' MAGNITUDE Phase 3 trial allows the company to continue its research on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), resulting in a nearly 10% surge in pre-market shares.
- Enhanced Safety Measures: Intellia has agreed with the FDA to implement new safety monitoring protocols, including closer liver function monitoring, short-term steroid treatment if necessary, and stricter patient screening to ensure the trial's safety and efficacy.
- Patient Exclusion Criteria: Under the new measures, patients with liver issues or serious heart instability will be excluded from the trial, a strategy aimed at reducing potential side effect risks and increasing the likelihood of clinical trial success.
- Trial Scale and Objectives: The MAGNITUDE trial is set to enroll approximately 1,200 patients to evaluate the safety and effectiveness of a single dose of nexiguran ziclumeran (nex-z) compared to placebo, potentially offering new hope for ATTR-CM treatment.
See More
Intellia Receives FDA Lift on Clinical Hold for Nex-z Trials
- Clinical Trial Advancement: Intellia Therapeutics announced that the FDA has lifted the clinical hold on its MAGNITUDE Phase 3 trial, allowing the continuation of research on nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy, marking a significant advancement in treatment development.
- Patient Safety Measures: To ensure patient safety, Intellia has aligned with the FDA to implement measures including enhanced monitoring of liver function and exclusion of patients with certain liver abnormalities, which will help mitigate potential risks and improve the likelihood of trial success.
- Trial Scale and Design: The MAGNITUDE trial aims to enroll approximately 1,200 patients using a randomized, double-blind, placebo-controlled design, primarily assessing a composite measure of cardiovascular-related events, which is expected to provide critical data support for the treatment of ATTR-CM.
- Market Potential: Based on CRISPR technology, if successful, nex-z could become the first one-time treatment for ATTR-CM, presenting significant market potential and substantially enhancing Intellia's competitiveness in the biopharmaceutical sector.
See More
Intellia Therapeutics Q4 2025 Earnings Call Insights
- Clinical Trial Progress: Intellia completed enrollment of 80 patients in the HAELO Phase III trial in Q4 2025, demonstrating strong patient and physician interest in lonvo-z, with market research indicating that 99% of surveyed patients would consider using the drug, highlighting its significant market potential.
- Improved Financial Position: As of December 31, 2025, Intellia reported $605.1 million in cash and cash equivalents, which is expected to be sufficient to support the company through key milestones in the second half of 2027, indicating financial stability.
- Regulatory Update: The FDA lifted the clinical hold on MAGNITUDE-2 in January 2026, allowing resumed enrollment, reflecting positive regulatory progress, although liver safety concerns remain a critical issue to monitor.
- Commercial Strategy Development: The CFO stated plans to continue scaling the sales and reimbursement teams, finalizing distribution models and pricing strategies, with a projected U.S. launch of lonvo-z in the first half of 2027, demonstrating the company's proactive market readiness.
See More
INTELLIA THERAPEUTICS STOCK RISES 2% FOLLOWING US FDA'S LIFTING OF CLINICAL HOLD ON HEART DISEASE GENE THERAPY TRIAL
- Stock Performance: Intelia Therapeutics shares increased by 2% following a positive development in their clinical trial results.
- Clinical Trial Focus: The trial is centered on gene therapy for treating heart disease, specifically targeting a gene associated with the condition.
See More
Intellia Therapeutics FDA Lifts Clinical Hold on Nexizuran Trials
- Clinical Trial Progress: Intellia Therapeutics announced that the FDA has lifted the clinical hold on its phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), resulting in a 12% stock price increase on Monday, reflecting renewed market confidence in the drug.
- Historical Context: The clinical holds were imposed in October due to observed Grade 4 liver transaminase elevations and increased total bilirubin in a patient treated with nex-z, but both the MAGNITUDE and MAGNITUDE-2 trials have had their holds lifted, indicating progress in addressing safety concerns.
- Partnership Dynamics: The development of nex-z is in collaboration with Regeneron Pharmaceuticals, highlighting a joint effort to provide new treatment options for patients suffering from hereditary transthyretin amyloidosis with polyneuropathy, which could enhance patient outcomes.
- Financial Performance: Intellia reported a GAAP EPS of -$0.83 for Q4 2025, beating expectations by $0.12, while revenue reached $23.02M, exceeding forecasts by $10.85M, showcasing the company's potential in research and market expansion.
See More
Intellia Therapeutics Receives FDA Approval for Clinical Trial
- FDA Lifts Clinical Hold: The FDA has lifted the clinical hold on Intellia's MAGNITUDE trial, allowing the company to continue evaluating the efficacy and safety of nex-z in patients with transthyretin amyloidosis, which accelerates the advancement of its treatment options.
- Trial Enrollment Plans: Intellia aims to complete enrollment of approximately 1,200 patients in the MAGNITUDE trial and 60 patients in the MAGNITUDE-2 trial, ensuring data integrity and smooth trial progression, thereby laying the groundwork for future drug approval.
- Positive Stock Reaction: Intellia's shares rose 8.85% on Monday, reflecting a strong market reaction to the FDA's decision, with a 20% increase over the past 12 months indicating a favorable long-term trend for the company.
- Optimistic Analyst Ratings: The stock carries a Buy rating with an average price target of $19.73, with Chardan Capital and HC Wainwright & Co. maintaining and raising their targets, indicating strong market confidence in Intellia's future developments.
See More
Intellia's Shares Jump as FDA Lifts Hold on Nexiguran Trial
- FDA Lifts Clinical Hold: The FDA's decision to lift the clinical hold on Intellia Therapeutics' MAGNITUDE Phase 3 trial allows the company to continue its research on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), resulting in a nearly 10% surge in pre-market shares.
- Enhanced Safety Measures: Intellia has agreed with the FDA to implement new safety monitoring protocols, including closer liver function monitoring, short-term steroid treatment if necessary, and stricter patient screening to ensure the trial's safety and efficacy.
- Patient Exclusion Criteria: Under the new measures, patients with liver issues or serious heart instability will be excluded from the trial, a strategy aimed at reducing potential side effect risks and increasing the likelihood of clinical trial success.
- Trial Scale and Objectives: The MAGNITUDE trial is set to enroll approximately 1,200 patients to evaluate the safety and effectiveness of a single dose of nexiguran ziclumeran (nex-z) compared to placebo, potentially offering new hope for ATTR-CM treatment.
See More
Intellia Receives FDA Lift on Clinical Hold for Nex-z Trials
- Clinical Trial Advancement: Intellia Therapeutics announced that the FDA has lifted the clinical hold on its MAGNITUDE Phase 3 trial, allowing the continuation of research on nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy, marking a significant advancement in treatment development.
- Patient Safety Measures: To ensure patient safety, Intellia has aligned with the FDA to implement measures including enhanced monitoring of liver function and exclusion of patients with certain liver abnormalities, which will help mitigate potential risks and improve the likelihood of trial success.
- Trial Scale and Design: The MAGNITUDE trial aims to enroll approximately 1,200 patients using a randomized, double-blind, placebo-controlled design, primarily assessing a composite measure of cardiovascular-related events, which is expected to provide critical data support for the treatment of ATTR-CM.
- Market Potential: Based on CRISPR technology, if successful, nex-z could become the first one-time treatment for ATTR-CM, presenting significant market potential and substantially enhancing Intellia's competitiveness in the biopharmaceutical sector.
See More
Intellia Therapeutics Q4 2025 Earnings Call Insights
- Clinical Trial Progress: Intellia completed enrollment of 80 patients in the HAELO Phase III trial in Q4 2025, demonstrating strong patient and physician interest in lonvo-z, with market research indicating that 99% of surveyed patients would consider using the drug, highlighting its significant market potential.
- Improved Financial Position: As of December 31, 2025, Intellia reported $605.1 million in cash and cash equivalents, which is expected to be sufficient to support the company through key milestones in the second half of 2027, indicating financial stability.
- Regulatory Update: The FDA lifted the clinical hold on MAGNITUDE-2 in January 2026, allowing resumed enrollment, reflecting positive regulatory progress, although liver safety concerns remain a critical issue to monitor.
- Commercial Strategy Development: The CFO stated plans to continue scaling the sales and reimbursement teams, finalizing distribution models and pricing strategies, with a projected U.S. launch of lonvo-z in the first half of 2027, demonstrating the company's proactive market readiness.
See More
